UNSPSC 51373433: Chlorpheniramine/hydrocodone/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373433 Chlorpheniramine/hydrocodone/phenylephrine is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications to support community health initiatives, emergency response programs, and public health facilities. Recent solicitations show purchasing bodies acquiring these products through both direct procurement and cooperative purchasing arrangements, with vendors supplying through authorized pharmaceutical wholesalers and delivering to county health buildings, state facilities, and networked local government sites. The issuing bodies include county health departments (Seminole County, Florida) and state-level cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP, serving participating state and local facilities across multiple states including Oregon).

Activity under this code clusters in Florida and the Upper Midwest, with the most recent opportunities posted in mid-2026. Seminole County, Florida issued an IFB on June 30, 2026 (IFB60459723LAS) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. MMCAP issued an RFP (S1070000015802) posted January 20, 2026 with proposals due March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities; vendors must supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, or Morris & Dickson Co., LLC, with awarded vendors effective July 1, 2026. Both solicitations require vendors to maintain comprehensive insurance, comply with FDA and Drug Supply Chain Security Act requirements, and submit pricing in detailed format with specific National Drug Codes and packaging configurations.